Form 4: MDxHealth Executive Receives Stock Option Grant

MDxHealth officer Joseph Sollee was granted 237,100 stock options with an exercise price of $0.76.

Summary

• Reporting person Joseph Sollee received two separate grants of stock options on June 1, 2026.
• The first grant consists of 83,000 options subject to performance-based vesting criteria.
• The second grant consists of 154,100 options vesting in three equal annual installments.
• Both grants have an exercise price of $0.76 per share and an expiration date of May 28, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive compensation with long-term shareholder interests through equity-based incentives.
• Inclusion of performance-based vesting criteria for a portion of the grant, incentivizing company growth.

Negatives

• Potential for future share dilution upon the exercise of the granted options.

Risks

• Vesting of performance-based options is contingent upon meeting specific company criteria, which may not be achieved.
• Market price volatility could impact the value of the options and the incentive structure for the executive.

Future Outlook

The options are set to vest over the next three years for the time-based portion, with performance-based options vesting upon the achievement of specific company criteria.

Management Comments

• The grants are intended to align the interests of the officer with the company's performance and long-term value creation.

Industry Context

StockSavvy.ai notes that equity grants for key personnel are standard practice in the biotech and diagnostics sector to retain talent and incentivize performance, particularly for companies in growth phases.

Comparison to Industry Standards

• The use of a mix of time-based and performance-based vesting is consistent with industry best practices for executive compensation.
• The 10-year expiration term is standard for employee stock option plans in the life sciences industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the 154,100 time-based options over the next three years.
• Evaluation of performance criteria by the Board of Directors for the 83,000 performance-based options.

Key Dates

Keywords

MDxHealth, MDXH, Form 4, Stock Options, Executive Compensation, Insider Transaction